Table 1 Baseline characteristics of GOLD group B patients according to FEV1 level
| Â | All | GOLD III/IV | GOLD I/II |
|---|---|---|---|
Number of patients | 14449 | 8043 | 6406 |
Age | 64.7 ± 8.6 | 64.7 ± 8.4 | 64.6 ± 8.9 |
Male | 9960 (68.9) | 5821 (72.4) | 4139 (64.6) |
Current smoker | 6384 (44.2 | 3455 (43.0) | 2929 (45.7) |
Smoking pack-years | 46.2 ± 22.2 | 44.3 ± 22.2 | 48.6 ± 22.0 |
Body mass index | 26.8 ± 5.8 | 26.3 ± 5.8 | 27.4 ± 5.8 |
FEV1, L | 1.2 ± 0.5 | 1.0 ± 0.3 | 1.5 ± 0.4 |
FEV1, %pred | 43.8 ± 13.5 | 35.1 ± 9.3 | 54.6 ± 9.2 |
No of exacerbation in the preceding year | |||
 0 | 11,778 (81.5) | 6471 (80.5) | 5307 (82.8) |
 1 | 2671 (18.5) | 1572 (19.5) | 1099 (17.2) |
Treatment | |||
 LABA/LAMA |  |  |  |
  Tiotropium/olodaterol | 4528 (31.3) | 2510 (31.2) | 2018 (31.5) |
  Umeclidinium/vilanterol | 1487 (10.3) | 796 (9.9) | 691 (10.8) |
  Glycopyrronium/indacaterol | 791 (5.5) | 492 (6.1) | 299 (4.7) |
 LAMA |  |  |  |
  Tiotropium | 4869 (33.7) | 2651 (33.0) | 2218 (34.6) |
  Glycopyrronium | 469 (3.2) | 298 (3.7) | 171 (2.7) |
  Umeclidinium | 522 (3.6) | 289 (3.6) | 233 (3.6) |
 LABA |  |  |  |
  Indacaterol | 624 (4.3) | 411 (5.1) | 213 (3.3) |
  Olodaterol | 658 (4.6) | 331 (4.1) | 327 (5.1) |
  Vilanterol | 501 (3.5) | 265 (3.3) | 236 (3.7) |